| dbo:abstract
|
- Lilotomab (formerly tetulomab, HH1) is a murine monoclonal antibody against CD37, a glycoprotein which is expressed on the surface of mature human B cells. It was generated at the Norwegian Radium Hospital. As of 2016 it was under development by the Norwegian company Nordic Nanovector ASA as a radioimmunotherapeutic in which lilotomab is conjugated to the beta radiation-emitting isotope lutetium-177 by means of a linker called satetraxetan, a derivative of DOTA. This compound is called 177Lu-HH1 or lutetium (177Lu) lilotomab satetraxetan (trade name Betalutin). As of 2016, a phase 1/2 clinical trial in people with non-Hodgkin lymphoma was underway. (en)
|
| dbo:casNumber
|
- (lutetium (177Lu) lilotomab satetraxetan)
- 1453362-55-4
|
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:thumbnail
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 4589 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:casNumber
| |
| dbp:chemspiderid
| |
| dbp:kegg
| |
| dbp:mabType
| |
| dbp:source
| |
| dbp:synonyms
| |
| dbp:target
| |
| dbp:type
| |
| dbp:unii
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| rdf:type
| |
| rdfs:comment
|
- Lilotomab (formerly tetulomab, HH1) is a murine monoclonal antibody against CD37, a glycoprotein which is expressed on the surface of mature human B cells. It was generated at the Norwegian Radium Hospital. (en)
|
| rdfs:label
| |
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
